Eledon Pharmaceuticals, Inc.
No enriched coverage for $ELDN in the last 7 days.
No SEC Form 4 filings for $ELDN in the last 30 days.
Eledon Pharmaceuticals (NASDAQ:ELDN) reported a March 2026 balance sheet (May 2026) with $111m cash and no debt. The company’s cash burn was $69m over the prior year, implying about a 19-month runway. It recorded no revenue and cash burn rose 26%. Cash burn equals about 24% of its $289m market cap.
Analysts initiated coverage on several stocks. BMO Capital began coverage of Insmed (NASDAQ:INSM) with an Outperform rating and $192 target, and Axsome Therapeutics (NASDAQ:AXSM) with an Outperform rating and $310 target. Compass Point started American Healthcare REIT (NYSE:AHR) at Buy with $70 target. BMO initiated Trevi Therapeutics (NASDAQ:TRVI) at Outperform with $36 target, and Rodman & Renshaw started Eledon Pharmaceuticals (NASDAQ:ELDN) at Buy with $12 target.
NewcelX (Nasdaq: NCEL) said it completed a Type B Pre-IND meeting with the FDA for NCEL-101 in type 1 diabetes, with FDA feedback aligning on a regulatory path toward IND-enabling activities and a planned clinical trial. The trial would combine NCEL-101 with Eledon Pharmaceuticals’ (Nasdaq: ELDN) tegoprubart (anti-CD40L).
Recent ELDN coverage spans financial news, regulation and corporate actions.
Rising cash burn increases dilution risk if additional financing is needed before runway ends.
Bullish initiation may support speculative interest, but it is not equivalent to new trial data or regulatory progress.
The FDA-aligned combination plan can be read as progress toward a clearer development pathway for tegoprubart in islet transplantation settings.
Authorized-share increase can expand future dilution capacity; near-term impact depends on whether the company plans to issue shares soon.
Updated clinical outcomes strengthen the efficacy/safety narrative for tegoprubart and support FDA discussions for a potential path to market.
alphai scores every news story that mentions ELDN with an AI model for sentiment and relevance, and aggregates insider trades from Eledon Pharmaceuticals, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Eledon Pharmaceuticals (NASDAQ:ELDN) reported a March 2026 balance sheet (May 2026) with $111m cash and no debt. The company’s cash burn was $69m over the prior year, implying about a 19-month runway. It recorded no revenue and cash burn rose 26%. Cash burn equals about 24% of its $289m market cap.
5 min readAnalysts initiated coverage on several stocks. BMO Capital began coverage of Insmed (NASDAQ:INSM) with an Outperform rating and $192 target, and Axsome Therapeutics (NASDAQ:AXSM) with an Outperform rating and $310 target. Compass Point started American Healthcare REIT (NYSE:AHR) at Buy with $70 target. BMO initiated Trevi Therapeutics (NASDAQ:TRVI) at Outperform with $36 target, and Rodman & Renshaw started Eledon Pharmaceuticals (NASDAQ:ELDN) at Buy with $12 target.
2 min readNewcelX (Nasdaq: NCEL) said it completed a Type B Pre-IND meeting with the FDA for NCEL-101 in type 1 diabetes, with FDA feedback aligning on a regulatory path toward IND-enabling activities and a planned clinical trial. The trial would combine NCEL-101 with Eledon Pharmaceuticals’ (Nasdaq: ELDN) tegoprubart (anti-CD40L).
3 min readEledon Pharmaceuticals, Inc. (ELDN) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K 0001404281 false --12-31 0001404281 2026-06-18 2026-06-18 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): J
3 min readEledon Pharmaceuticals (ELDN) reported updated investigator-initiated trial results for tegoprubart, an anti-CD40L antibody, in type 1 diabetes patients receiving allogeneic islet cell transplants at the University of Chicago. According to the company, all 12 patients achieved insulin independence, with mean most recent HbA1c ~5.4% and stable graft function over a median 8 months (max 22). No rejection or de novo donor-specific HLA antibodies were reported. Eledon said it will seek FDA regulator
4 min readEledon Pharmaceuticals Inc. (ELDN) has filed an SEC Form DEFA14A. The article also provides recent analyst ratings for ELDN, including targets from H.C. Wainwright, Guggenheim, Cantor Fitzgerald, and HC Wainwright & Co., alongside a list of related SEC filings and press releases concerning the company.
3 min readData from Phase 2 BESTOW trial demonstrated a favorable safety and tolerability profile, substantially reducing the metabolic, neurologic, and cardiovascular toxicities commonly associated with tacrolimus
3 min readIRVINE, Calif., Nov. 12, 2025 ( GLOBE NEWSWIRE ) -- Eledon Pharmaceuticals, Inc. ( "Eledon" ) ( NASDAQ:ELDN ) , today announced the pricing of its underwritten public offering of ( i ) 15,152,485 shares of its common stock at a public offering price of $1.65 per share and ( ii ) in lieu of ...
3 min readIRVINE, Calif., Nov. 11, 2025 ( GLOBE NEWSWIRE ) -- Eledon Pharmaceuticals, Inc. ( "Eledon" ) ( NASDAQ: ELDN ) , today announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase ...
3 min readEledon Pharmaceuticals, Inc. ( NASDAQ:ELDN ) stock is trading lower on Friday, with a session volume of 15.72 million, compared to its average volume of 1.24 million, according to Benzinga Pro.
2 min read
